Brokers Offer Predictions for ARTV FY2025 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report issued on Tuesday, March 25th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($2.91) per share for the year, down from their previous estimate of ($2.72). Cantor Fitzgerald has a “Overweight” rating and a $20.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

A number of other research firms have also issued reports on ARTV. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV opened at $3.64 on Thursday. The company’s 50 day moving average is $4.84 and its 200-day moving average is $9.33. Artiva Biotherapeutics has a 12 month low of $3.37 and a 12 month high of $17.31.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics during the third quarter worth about $42,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Artiva Biotherapeutics in the 4th quarter worth approximately $52,000. Wells Fargo & Company MN grew its holdings in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after purchasing an additional 3,361 shares in the last quarter. MetLife Investment Management LLC bought a new stake in shares of Artiva Biotherapeutics during the third quarter valued at approximately $135,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Artiva Biotherapeutics in the third quarter valued at $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.